未知生产厂商
Tabelecleucel is a medication that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disorder.
Tabelecleucel is a medication that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disorder.
Human B cells are the main targets of Epstein-Barr virus (EBV). In immunocompetent people, EBV usually has mild effects, but in immunocompromised patients, an EBV infection can lead to potentially life-threatening consequences. For instance, patients that have gone through solid organ or bone marrow transplantation may develop EBV-associated post-transplant lymphoproliferative disorder (PTLD), a type of cancer or lymphoma caused by an uncontrolled growth of cells in lymph nodes and other organs. Tabelecleucel consists of EBV-specific allogeneic cytotoxic T cells (CTLs) that specifically target EBV-infected B-cells, helping to control EBV-associated cancers.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
